Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib

  This study aimed to evaluate the steroid-sparing effect of tofacitinib in patients with RA. To the best of our knowledge, this is the first prospective study that evaluated the feasibility of a predetermined schedule for GCs discontinuation in patients initiating tofacitinib treatment. This showed that already 12 weeks after starting treatment, 30% of patients…